We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for ...

Over the last decade, TNF-α antagonists became the most powerful tools for controlling patient suffering from a number of rheumatic diseases. Infliximab, etanercept and adalimumab can induce ...

Inhibiting the entire receptor complex ... Since IL-6R inhibition has a distinct mechanism of action, some patients who do not respond to antitumor necrosis factor agents or who have a partial ...

SU11657 (SUGEN) is a selective multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity exerted by targeting PDGF receptors ... of apoptosis and necrosis, in all three ...

The FDA has cleared the IL-36 receptor inhibitor under the Spevigo ... drugs that inhibit other cytokines – including TNF, IL-17 and IL-23 inhibitors – are used off-label to try to support ...

To advance from resection-based interventions, which can compromise life-saving hypoxic ventilatory responses, alternative strategies that target signaling by PACAP (eg, PACAP type 1 receptor), LPA ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

Fig 1. CONSORT diagram (patient disposition). HER3, human epidermal growth factor receptor 3; PD, progressive disease. Fig 2. Kaplan-Meier plots of (A) PFS and (B) DOR, both by BICR per RECIST 1.1.

previous antiangiogenic therapies/VEGFR-2 inhibitors. Written informed consent from all patients and approval from the institutional review boards was obtained. Telatinib was administered orally, once ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system. Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of ...

A common sleep aid restores healthier sleep patterns and protects mice from the brain damage seen in neurodegenerative ...